COMPARE · Data as of August 27, 2026
ALNY vs ARQT
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 75.1, ARQT scored 66.1 — ALNY leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
75.1
$236.56 · $31.7B
fundamentals as of
Score gap
9.0
ALNY leads
ARQT
Arcutis Biotherapeutics, Inc.
66.1
$24.87 · $3.1B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestALNY41.2x
- Fastest growthARQT+76.1%
- Strongest balance sheetARQT0.52
- Highest qualityALNY67 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
ARQT
67
Qualityreturns · margins · balance sheet
47
99
Growthrevenue & earnings expansion
100
64
Valuevaluation vs sector peers
62
ALNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
ARQT
$465mC
FCF
$39mC-
+65.2%A
Rev
+76.1%A
2.21D
D/E
0.52B
41.2xC
P/E
113.0xD
0.45A
PEG
0.52A-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
ARQT
190% above
Price vs fair valuelower is cheaper
386% above
~43%/yr
Growth the price implies10-yr FCF · lower = less priced in
>60%/yr
-74%
1-yr DCF upside
-84%
-65%
5-yr DCF upside
-79%
-48%
10-yr DCF upside
-70%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
ARQT
Why this score
- Diluting shareholders
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $31.7b. Down 52% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.45 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $370.20 (implying +56% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
ARQTArcutis Biotherapeutics, Inc.
Why now
Biotechnology · market cap $3.1b. Down 22% from 52-week high of $31.77 — deep drawdown territory. Revenue growing +76% — in hypergrowth territory. PEG 0.52 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $36.88 (implying +48% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 113.0x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Beta 1.53 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and ARQT diverge
On the headline score the gap is 9.0 points in favor of ALNY. The widest single difference is Quality, where ALNY leads by 20.0 points.
- QualityALNY 66.8 · ARQT 46.8ALNY +20.0
- ValueALNY 64.4 · ARQT 61.9level
- GrowthALNY 98.5 · ARQT 99.7level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.